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ORIGINAL ARTICLE
INTRODUCTION
Superior vena cava obstruction (SVCO) was first de-
scribed by Hunter in 1757 in a patient with a syphilitic
aneurysm of the ascending aorta.1 Nowadays, the ma-
jority of cases are due to malignant tumour within the
mediastinum — namely, lung cancer and lymphoma.2
The pathology of SVCO is extrinsic compression of the
large central veins feeding into the heart, sometimes
accompanied by intravascular tumours or thrombosis.
The presenting symptoms are dyspnoea, dilatation of
neck veins, and swelling of soft tissues of the face, neck,
and upper limbs. Headache and other cranial symptoms
may occur as a result of cerebral oedema.3,4 SVCO often
arises acutely and should be treated as an oncological
emergency.5 It is usually highly responsive to radio-
therapy (RT), regardless of tumour type.6 Therefore,
active treatment should be considered unless the
patient is extremely ill, or is unable or unwilling to
attend for RT.7 High-dose corticosteroid therapy is
usually given to reduce oedema associated with medi-
astinal tumour.8 Recently, it has been suggested that an
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ABSTRACT
Superior vena cava obstruction is, in the majority of patients, due to the presence of a malignant tumour
within the mediastinum, i.e. lung cancer and lymphoma. It is usually highly responsive to radiotherapy,
regardless of the underlying tumour type. This article briefly reviews the diagnosis, presentation, and results
of radiotherapy in a total of 49 patients with superior vena cava obstruction who presented to the depart-
ment of clinical oncology at the Pamela Youde Nethersole Eastern Hospital between 1 January 1996 and
31 December 1999. Lung cancer accounted for the majority of cases of superior vena cava obstruction. The
most common presenting symptoms were facial and upper limb oedema; all patients presented with a history
of symptoms of less than 3 months duration. The median survival was 6 weeks after diagnosis. Radiotherapy
was well tolerated and produced good symptom relief.
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accurate histological diagnosis be obtained in advance
in order to establish the correct, effective therapy.5
Symptomatic relief following irradiation is reported in
50% to 90% of cases; survival of patients with SVCO
is determined by their underlying disease rather than by
the syndrome itself.9-11
PATIENTS AND METHODS
The present study is a retrospective analysis of pa-
tients with SVCO who presented to the department of
clinical oncology, Pamela Youde Nethersole Eastern
Hospital, Hong Kong, between 1 January 1996 and 31
December 1999. Medical records of these patients
were retrieved and analysed, specifically for diagnosis,
symptom(s), duration of presenting symptom(s), symp-
tomatic relief, and RT dosage (dose/fraction, number
of fractions, total dose, and overall treatment time).
Statistical Analysis
Statistical analysis was performed using the Statistical
Package for the Social Sciences (version 8.0). Unless
otherwise stated, all results are expressed as number [no.]
(%) or mean –  standard deviation (SD) where appropriate.
RESULTS
A total of 49 patients were analysed in this study. There
were 34 (69.4%) male and 15 (30.6%) female patients.
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The median age at presentation was 69 years (range, 15
to 86 years). The mean follow-up time was 10.6 –
11.9 weeks (range, 0.1 to 50.0 weeks). Symptoms at
presentation were as follows: facial and upper limb
oedema in 36 patients (73.5%), dyspnoea in 30 (61.2%),
distension of neck veins in 30 (61.2%), chest pain in 3
(6.1%), and cough in 12 (24.5%). None of the patients
presented with symptoms of increased intracranial
pressure. The mean duration of presenting symptoms
was 26.8 days (range, 1 to 90 days). All patients pre-
sented with a history of symptoms of less than 3 months
duration. Among the 49 patients, 38 (77.6%) had a
histological diagnosis while 11 (22.4%) had a clinical
diagnosis only. The patients’ diagnoses are summarised
in Table 1.
Forty eight patients (98.0%) received RT. The remain-
ing patient was too sick to receive active treatment.
Forty one patients completed the course of RT and the
median total dose was 28 Gy in seven daily fractions
over 10 days. The results of treatment in different groups
of patients are summarised in Table 2. Overall, symp-
tomatic relief was reported for 38 patients (79.2%).
The percentage and duration of symptomatic relief are
summarised in Table 3. Of the 40 patients who started
dexamethasone before RT, 30 (75.0%) had decreased
dexamethasone requirement after RT and 13 (32.5%)
eventually stopped the corticosteroid altogether. The
median survival of the whole group was 6 weeks (range,
1 to 56 weeks) after diagnosis.
DISCUSSION
The majority of patients in this study presented with
facial and upper limb oedema — a prominent feature
causing them to seek medical treatment. The other
common presenting symptoms were cough, distension
of neck veins, and dyspnoea. None of the patients pre-
sented with cranial symptoms due to cerebral oedema.
Thus, these findings are in accordance with previously
published data showing dyspnoea and facial and upper
limb oedema to be the most common symptoms in
SVCO,6,11,12 while cranial symptoms are rare.9
Bronchogenic carcinoma accounted for the majority of
the cases of SVCO in this series (79.6%), followed by
lymphoma. These findings are again consistent with
those in the literature.8,13 However, only patients with
malignant disease causing SVCO were included in our
review; non-malignant causes such as mediastinal
fibrosis and thrombosis of the superior vena cava (which
account for a proportion of cases in general hospitals)
were not seen here.14,15 The reason for this may be due to a
different referral pattern to a clinical oncology department.
A lower rate of symptom relief was observed in patients
receiving both corticosteroid therapy and RT compared
with those receiving RT alone (Table 2). The reason
for this may be the fact that those who received both
corticosteroid therapy and RT had poorer performance
status and worse symptoms at the outset; as a result,
they responded less well to treatment. On the other
hand, patients with milder symptoms and better per-
formance status at presentation did not require cortico-
steroid therapy and responded well to RT.
In our study, treatment of SVCO was mostly palliative,
with a total radiation dose of 28 Gy. According to the
literature, a total dose of 20 Gy in five fractions or 30
Gy in 10 fractions is usually adequate for palliation.
The choice of total dose and fractionation schedules
depends on the histology of the tumour.16 RT was
usually well tolerated and resulted in significant symp-
tomatic improvement. Treatment could be completed
in most of the patients (>80%), and the symptoms






Carcinoma of thyroid 1 (2.0)
Thymoma 1 (2.0)
Metastatic carcinoma 6 (12.2)
Abbreviations: NSCLC = non-small cell lung cancer; SCLC = small cell lung
cancer.
Table 2  Results of treatment in different groups of patients with
superior vena cava obstruction
Patient group No. (%) Symptom relief
after RT (%)
NSCLC 33 (67.3) 78.8
Other diagnosis 16 (32.7) 81.3
Corticosteroid therapy and RT 39 (79.6) 76.9
RT only 9 (18.4) 100
Table 3. Improvement of patients’ symptoms after radiotherapy
(RT)
Symptom Symptom relief Median duration
after RT (%) of symptom relief
(weeks)
Dyspnoea 73.3 6.6 –  2.0
Facial and upper limb oedema 80.6 13.9 –  3.4
Distension of neck veins 76.7 14.8 –  4.0
Chest pain 66.7 10.9 –  6.6
Cough 85.7 7.7 –  3.7
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that were best controlled included cough and facial
and upper limb oedema. Among all the symptoms,
relief of the distension of neck veins and facial and
upper limb oedema were the most durable.
The treatment results of this study were comparable
with most of the reported overseas series.9-11 For patients
with SVCO secondary to non-small cell lung cancer,
RT is the primary treatment. The likelihood of reliev-
ing signs and symptoms of SVCO is high, but the over-
all prognosis for these patients is poor.8,10,11,15 RT has
been advocated as standard treatment for most patients
with SVCO.9,17,18 It is used as the initial treatment if a
histological diagnosis cannot be established while, at
the same time, the clinical status of the patient is
deteriorating.13 Armstrong et al observed improvement
of symptoms within 2 weeks or less in 70% of irradi-
ated patients.11 Serial venography and autopsy findings
suggest that the symptomatic improvement achieved
after RT is not always due to improvement of flow
through the superior vena cava, but is probably also
a result of the development of collaterals after the
pressure in the mediastinum is eased.5
CONCLUSION
RT with a dose of 28 Gy in seven daily fractions in 10
days is usually well tolerated and produces good symp-
tom relief in patients with SVCO. Our retrospective
analysis described the outcome of patients treated mainly
by RT; the results were in accordance with the existing
published literature.
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